ZIOP ZIOPHARM Oncology Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(Rule 14a-101)

 

INFORMATION REQUIRED IN CONSENT STATEMENT

 

SCHEDULE 14A INFORMATION

 

Consent Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934

 

(Amendment No. )

 

Filed by the Registrant ☐

 

Filed by a Party other than the Registrant ☒

 

Check the appropriate box:

 

☐

Preliminary Consent Statement

 

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐

Definitive Consent Statement

 

☒

Definitive Additional Materials

 

☐

Soliciting Material Under Rule 14a-12

  

ZIOPHARM ONCOLOGY, INC.

(Name of Registrant as Specified in Its Charter)

ROBERT W. POSTMA WATERMILL ASSET MANAGEMENT CORP. JAIME VIESER HOLGER WEIS

(Name of Persons(s) Filing Consent Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒

No fee required.

 

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

(1)

Title of each class of securities to which transaction applies:

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

(5)

Total fee paid:

 

 

☐

Fee paid previously with preliminary materials:

  

 

☐          Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

 

(1)

Amount previously paid:

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

(3)

Filing Party:

 

 

(4)

Date Filed:

 

 

WaterMill Asset Management Corp., together with the other participants named herein (collectively, “WaterMill”), has filed a definitive consent statement and accompanying WHITE consent card with the Securities and Exchange Commission to be used to solicit consents from shareholders of Ziopharm Oncology, Inc., a Delaware corporation (the “Company”), for a number of proposals, the ultimate effect of which, if successful, would be to reconstitute the Board of Directors of the Company (the “Board”) through the removal of four current members of the Board and the election of WaterMill’s three highly-qualified nominees.

 

Item 1: On November 21, 2020, Watermill delivered the following email to subscribers of www.FixZiopharm.com:

The need for change atop Ziopharm.

Fellow Shareholder,

This week we released a detailed presentation outlining the case for urgent change at Ziopharm.

We firmly believe that Ziopharm is on a path to financial ruin as its capital position shrinks, G&A and R&D costs rise, and value-generating pipeline progress remains evasive.

We believe the WaterMill Slate - Robert Postma, Jaime Vieser and Holger Weis - has the business acumen, capital allocation expertise, financing relationships, and commercial creativity required to stave off disaster and spark an enduring turnaround at Ziopharm.

Our director candidates are committed to restoring confidence and faith in Ziopharm after five dismal years.

As a reminder, you can share your candid thoughts with us at www.FixZiopharm.com.

Help us build a better Ziopharm for all shareholders by consenting to all five of our proposals on the WHITE consent card today.

Sincerely,
Robert Postma

Principal and Founder
WaterMill Asset Management Corp.

Item 2: On November 23, 2020, WaterMill issued an additional Investor Presentation, which is attached hereto as Exhibit 99.1 and incorporated herein by reference, rebutting the Company’s November 19, 2020 presentation.

This regulatory filing also includes additional resources:
ex991dfan14a12766002_112320.pdf